Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bifidobacterium breve 207-1
- Development stage
- Preclinical
- Lead developer
- By-Health
- Modality
- Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bifidobacterium breve 207-1 is a probiotic and postbiotic strain originally isolated from the intestinal tracts of healthy newborns. It is deposited at the Guangdong Province Collection of Microorganisms under the accession number GDMCC No. 60962. The strain functions as a live biotherapeutic or heat-killed postbiotic, modulating the immune system by stimulating Interleukin-10 (IL-10) secretion and anti-inflammatory cytokine production. It also influences the microbiome-gut-brain axis to regulate neurotransmitters and HPA axis hormones, and targets the insulin/FOXO (daf-2/daf-16) signaling pathway to manage glycolipid metabolism. Research indicates potential applications in treating inflammatory diseases, mental health conditions like stress and insomnia, metabolic disorders such as obesity and constipation, and allergic symptoms. The strain is associated with patent CN114317320A, originating from the Guangdong Institute of Microbiology.
- Other names
- 短双歧杆菌207-1B. breve 207-1
02
Targets
IGF-1R (Insulin-like growth factor 1 receptor)IL10 (Interleukin-10)FOXO1 (Forkhead box protein O1)
Beyond the preview
Go deeper on Bifidobacterium breve 207-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bifidobacterium breve 207-1.